These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7249126)

  • 1. [Medical and economic analysis of the treatment of advanced cancer of the ovaries].
    Honzáková L; Dvorák O; Federmann J
    Cesk Zdrav; 1981 May; 29(5):181-90. PubMed ID: 7249126
    [No Abstract]   [Full Text] [Related]  

  • 2. [Medical-economic analysis of the treatment of advanced ovarian cancer].
    Dvorák O; Federmann J; Honzáková L
    Cesk Gynekol; 1982 Dec; 47(10):755-63. PubMed ID: 7159949
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment patterns, health care utilization, and costs of ovarian cancer in Central and Eastern Europe using a Delphi panel based on a retrospective chart review.
    Kim K; Hernlund E; Hernadi Z; Révész J; Pete I; Szánthó A; Bodnar L; Madry R; Timorek-Lemieszczuk A; Bozanovic T; Vasovic S; Tomasevic Z; Zivaljevic M; Pazin V; Minárik T; Garanová H; Helpianska L; Justo N
    Int J Gynecol Cancer; 2013 Jun; 23(5):823-32. PubMed ID: 23666016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resource utilization for ovarian cancer patients at the end of life: how much is too much?
    Lewin SN; Buttin BM; Powell MA; Gibb RK; Rader JS; Mutch DG; Herzog TJ
    Gynecol Oncol; 2005 Nov; 99(2):261-6. PubMed ID: 16140364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer.
    Doyle C; Crump M; Pintilie M; Oza AM
    J Clin Oncol; 2001 Mar; 19(5):1266-74. PubMed ID: 11230467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Medical consumption as a function of various socio-economic characteristics].
    Mizrahi A
    Cah Sociol Demogr Med; 1974; 14(2):37-42. PubMed ID: 4431392
    [No Abstract]   [Full Text] [Related]  

  • 7. [Calculation of the economic capital of health].
    Korchagin VP
    Sov Zdravookhr; 1981; (2):20-6. PubMed ID: 6782680
    [No Abstract]   [Full Text] [Related]  

  • 8. Medicaid payments and utilization of medical services by the poor.
    Davis K
    Inquiry; 1976 Jun; 13(2):122-35. PubMed ID: 132399
    [No Abstract]   [Full Text] [Related]  

  • 9. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(12):1227-59. PubMed ID: 11772158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggressive and complex surgery for advanced ovarian cancer: an economic analysis.
    Aletti GD; Podratz KC; Moriarty JP; Cliby WA; Long KH
    Gynecol Oncol; 2009 Jan; 112(1):16-21. PubMed ID: 19027146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population.
    Alemayehu B; Buysman E; Parry D; Becker L; Nathan F
    J Med Econ; 2010; 13(2):351-61. PubMed ID: 20491610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Impact Among Family Caregivers of Patients With Advanced Ovarian Cancer.
    Angioli R; Capriglione S; Aloisi A; Miranda A; de Cicco Nardone C; Terranova C; Adrower R; Plotti F
    Int J Gynecol Cancer; 2015 Oct; 25(8):1541-6. PubMed ID: 26270119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The end of life costs for Medicare patients with advanced ovarian cancer.
    Urban RR; He H; Alfonso R; Hardesty MM; Goff BA
    Gynecol Oncol; 2018 Feb; 148(2):336-341. PubMed ID: 29208368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer.
    Poonawalla IB; Lairson DR; Chan W; Piller LB; Du XL
    Value Health; 2015 Jun; 18(4):387-95. PubMed ID: 26091592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Retrospective Study of the Effects of Oncology Pharmacist Participation in Treatment on Therapeutic Outcomes and Medical Costs.
    Imamura M; Ogawa D; Takatori T; Yamaguchi M; Takata T; Hada T; Ota Y; Uehara T
    Biol Pharm Bull; 2017; 40(11):1956-1962. PubMed ID: 29093344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economic impact of false-positive cancer screens.
    Lafata JE; Simpkins J; Lamerato L; Poisson L; Divine G; Johnson CC
    Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2126-32. PubMed ID: 15598770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From randomised clinical trials to clinical practice : a pragmatic cost-effectiveness analysis of Paclitaxel in first-line therapy for advanced ovarian cancer.
    Limat S; Woronoff-Lemsi MC; Menat C; Madroszyk-Flandin A; Merrouche Y
    Pharmacoeconomics; 2004; 22(10):633-41. PubMed ID: 15244489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness research: a proposal for funding in ovarian cancer.
    Markman M
    Gynecol Oncol; 2009 Nov; 115(2):182-3. PubMed ID: 19695689
    [No Abstract]   [Full Text] [Related]  

  • 19. The economic costs of the health effects of smoking, 1984.
    Rice DP; Hodgson TA; Sinsheimer P; Browner W; Kopstein AN
    Milbank Q; 1986; 64(4):489-547. PubMed ID: 3102916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
    Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
    Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.